Biomaterial Database

Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. 1990

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Liver Unit, King's College Hospital, London, UK.

Seven chronic carriers of hepatitis B virus (HBV) were studied during treatment with interferon-alpha to determine whether tumour necrosis factor alpha (TNF alpha) or interleukin-1 beta (IL-1 beta) contributed to the elimination of HBV. Four patients responded to interferon-alpha with clearance of HBeAg and permanent inhibition of HBV replication within 3-12 weeks; in each of these patients, the changes were accompanied by substantial rises in spontaneous in-vitro production of TNF alpha and IL-1 beta by peripheral blood mononuclear cells from previously undetectable levels. There was little or no change in spontaneous TNF alpha and IL-1 beta production in the three patients who did not lose HBeAg in response to interferon-alpha. These findings suggest that TNF alpha and IL-1 beta may contribute to the permanent elimination during interferon-alpha treatment of hepatocytes supporting viral infection and that the therapeutic potential of these cytokines is worthy of investigation.

UI	MeSH Term	Description	Entries
D007370	Interferon Type I	Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).	Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007375	Interleukin-1	A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.	IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008070	Lipopolysaccharides	Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)	Lipopolysaccharide,Lipoglycans
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009000	Monocytes	Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.	Monocyte
D010446	Peptide Fragments	Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.	Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002353	Carrier State	The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host.	Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002908	Chronic Disease	Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004279	DNA, Viral	Deoxyribonucleic acid that makes up the genetic material of viruses.	Viral DNA

Related Publications

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Interferon-gamma, interleukin-1 and tumour necrosis factor-alpha synthesis during experimental murine staphylococcal infection.

August 1993, FEMS immunology and medical microbiology,

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections.

January 1994, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Interleukin-1 alpha- and beta-, interleukin-6- and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions.

November 1994, Acta dermato-venereologica,

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Cerebrospinal fluid concentrations of interleukin-1 beta, tumour necrosis factor-alpha, and interferon gamma in bacterial meningitis.

February 1994, Archives of disease in childhood,

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.

April 1991, Clinical and experimental immunology,

H M Daniels, and A Meager, and A L Eddleston, and G J Alexander, and R Williams

Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection.

August 1995, Immunology,